Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:China
gptkb:United_States |
| gptkbp:ATCCode |
L01EX24
|
| gptkbp:brand |
Elunate
Fruzaqla |
| gptkbp:CASNumber |
1194506-26-7
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
Hutchmed
|
| gptkbp:hasMolecularFormula |
C21H19FN4O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
fruquintinib
|
| gptkbp:indication |
metastatic colorectal cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
VEGFR inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
diarrhea hypertension proteinuria |
| gptkbp:target |
gptkb:VEGFR-1
gptkb:VEGFR-2 gptkb:VEGFR-3 |
| gptkbp:usedFor |
colorectal cancer
|
| gptkbp:bfsParent |
gptkb:Hutchison_MediPharma
|
| gptkbp:bfsLayer |
7
|